HRTX (Heron Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

HRTX (Heron Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

HRTXHeron Therapeutics, Inc.

Mkt Cap$162M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$155M

Net Income (TTM)-$20M

EPS (TTM)-$0.12

Free Cash Flow (TTM)-$28M

Gross Margin73.3%

Op. Margin-1.6%

Net Margin-13.0%

FCF Margin-18.0%

P/S Ratio (TTM)1.0x

P/E Ratio (TTM)—

YoY Rev Growth+7.4%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$30M	$13M	-$33M
Q2 23	$32M	$12M	-$42M
Q3 23	$31M	$13M	-$25M
Q4 23	$34M	$24M	-$10M
Q1 24	$35M	$26M	-$5M
Q2 24	$36M	$26M	-$6M
Q3 24	$33M	$23M	-$4M
Q4 24	$41M	$31M	$4M
Q1 25	$39M	$30M	$3M
Q2 25	$37M	$27M	-$2M
Q3 25	$38M	$23M	-$4M
Q4 25	$41M	$33M	$38K

Valuation

Quarter	P/S	P/E
Q1 23	1.4x	—
Q2 23	1.4x	—
Q3 23	1.3x	—
Q4 23	1.3x	—
Q1 24	1.2x	—
Q2 24	1.2x	—
Q3 24	1.2x	—
Q4 24	1.1x	—
Q1 25	1.1x	—
Q2 25	1.1x	—
Q3 25	1.0x	—
Q4 25	1.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$25M	-$25M
Q2 23	-$27M	-$27M
Q3 23	-$9M	-$10M
Q4 23	$2M	$2M
Q1 24	-$10M	-$10M
Q2 24	-$5M	-$5M
Q3 24	$3M	$3M
Q4 24	-$12M	-$12M
Q1 25	-$9M	-$9M
Q2 25	-$11M	-$11M
Q3 25	$1M	$1M
Q4 25	-$9M	-$9M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$224K
Q2 23	$278K
Q3 23	$793K
Q4 23	$250K
Q1 24	$0
Q2 24	$637K
Q3 24	$431K
Q4 24	$638K
Q1 25	$109K
Q2 25	$208K
Q3 25	$0
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+26.3%	-27.4%
Q2 23	+15.0%	-3.8%
Q3 23	+18.4%	-17.6%
Q4 23	+14.0%	-11.8%
Q1 24	+17.1%	-37.0%
Q2 24	+13.4%	-42.7%
Q3 24	+4.4%	-33.9%
Q4 24	+19.1%	-17.6%
Q1 25	+12.2%	-9.4%
Q2 25	+3.3%	-8.6%
Q3 25	+16.5%	+13.5%
Q4 25	-0.5%	+10.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$8M	26.8%
Q2 23	$14M	43.8%
Q3 23	$7M	21.3%
Q4 23	$4M	12.6%
Q1 24	$3M	9.7%
Q2 24	$5M	12.7%
Q3 24	$3M	8.3%
Q4 24	$2M	5.6%
Q1 25	$3M	6.5%
Q2 25	$3M	7.5%
Q3 25	$3M	7.5%
Q4 25	$2M	5.4%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$9M	$16M	$21M
Q2 23	$13M	$20M	$21M
Q3 23	$14M	$12M	$13M
Q4 23	$11M	$11M	$12M
Q1 24	$5M	$15M	$11M
Q2 24	$4M	$14M	$14M
Q3 24	$4M	$12M	$11M
Q4 24	$3M	$12M	$11M
Q1 25	$2M	$13M	$12M
Q2 25	$3M	$14M	$12M
Q3 25	$3M	$14M	$13M
Q4 25	$4M	$13M	$12M

Revenue Segments

Quarter	C I N V A N T I	S U S T O L	Z Y N R E L E F
Q1 23	$23M	$3M	$4M
Q2 23	$24M	$3M	$4M
Q1 24	$26M	$4M	$5M
Q2 24	$25M	$4M	$6M
Q3 24	$23M	$3M	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$27M	$33M	$60M
Q2 23	$13M	$20M	$33M
Q3 23	$35M	$43M	$77M
Q4 23	$29M	$52M	$80M
Q1 24	$20M	$51M	$72M
Q2 24	$18M	$49M	$67M
Q3 24	$26M	$45M	$71M
Q4 24	$26M	$33M	$59M
Q1 25	$19M	$31M	$51M
Q2 25	$17M	$24M	$41M
Q3 25	$43M	$12M	$55M
Q4 25	$29M	$18M	$47M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	119M	+0.1%
Q2 23	120M	+0.4%
Q3 23	145M	+21.1%
Q4 23	150M	+3.7%
Q1 24	151M	+0.6%
Q2 24	152M	+0.7%
Q3 24	153M	+0.3%
Q4 24	153M	+0.2%
Q1 25	153M	+0.2%
Q2 25	154M	+0.3%
Q3 25	170M	+10.6%
Q4 25	167M	-2.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$0	59
FY 15	$0	148
FY 16	$9K	139
FY 17	$212K	145
FY 18	$391K	198
FY 19	$632K	231
FY 20	$397K	223
FY 21	$286K	302
FY 22	$530K	203
FY 23	$1M	126
FY 24	$1M	122
FY 25	$1M	128